In this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium. He provided an update on rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban, and mentioned that all were better than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the …
Read More
StopAfib.org interviews Prof. Gregory Lip, of the University of Birmingham (UK) Find more information on the CHADS2 scoring system, and on Prof. Lip, at: http://www.stopafib.org/newsitem.cfm/NEWSID/369 In this video interview, Dr. Lip discussed the CHA2DS2-VASc tool, which was recently adopted by the European Society of Cardiology Atrial Fibrillation Guidelines for predicting stroke risk in atrial fibrillation. …
Read More
StopAfib.org interviews Dr. Elaine Hylek of Boston University. A transcript of this video, as well as additional information about the topics discussed, and Dr. Hylek, can be found at: http://www.stopafib.org/newsitem.cfm/NEWSID/349 In this video interview, Dr. Elaine Hylek of Boston University discusses new anticoagulant drugs for stroke prevention in atrial fibrillation. For many years, warfarin (Coumadin) …
Read More
In follow up to our announcement yesterday of the Top Ten Atrial Fibrillation Videos of 2011, StopAfib.org now unveils the Top Ten Atrial Fibrillation Articles of 2011. Major topics of interest to the atrial fibrillation patient community this year were afib stroke prevention and the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for …
Read More
StopAfib.org has announced the Top Ten Atrial Fibrillation Videos of 2011. Afib stroke prevention again topped the list, with stories about warfarin (Coumadin), alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto), and the CHADS2 and CHA2DS2-VASc scoring tools for determining whether anticoagulants are needed. Other popular topics included sleep apnea, catheter ablation, and maze procedures (surgical …
Read More
A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …
Read More
The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …
Read More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
Read More
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn …
Read More
The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed …
Read More